Study confirms Azilect as a selective MAO-B inhibitor

Links shared publicly online about this topic.

1,119
total visits

Study confirms Azilect as a selective MAO-B inhibitor

Teva Neuroscience Inc. today announced the publication of a study demonstrating the selectivity of Azilect® (rasagiline tablets) for inhibition of MAO-B (monoamine oxidase-B) at the maximum approved dose of 1 mg/day. The data was published in the Journal of Clinical Pharmacology OnlineFirst on May 5, 2010.

View full resource at news-medical.net

Tags: Health Insurance, Medicare